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Abstract
Cerebral abscess due to pigmented moulds are a rare but usually fatal infection 
occasionally seen in transplant recipients. A 67 year old male of Iraqi origin underwent a 
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with an abscess in the left posterior frontal lobe of his brain. Subsequent biopsy proved 
this to be due to the mould Rhinocladiella mackenziei. Further interventions included two 
operations to aspirate the lesion, voriconazole, then liposomal amphotericin B, then a 
combination of posaconazole and flucytosine which he continued for over four years. He 
also suffered from right ankle pain and was diagnosed with septic arthritis; R. mackenziei 
was isolated from pus aspirated from the ankle joint. He responded well to the treatment 
and has had little loss of function, and on CT the cerebral lesion has stabilised. Beta-D-
glucan, initially at very high levels proved useful to monitor response over the 5 years and 
the latest sample was negative
 (38 pg/mL). This case is notable for the first disseminated case of this infection, its 
favourable outcome on a novel antifungal combination and a new approach to monitoring 
the course of disease.
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Introduction
Rhinocladiella mackenziei  is a dematiaceous fungus and a rare cause of cerebral 
phaeohyphomycosis. It is thought that cerebral R. mackenziei infections are a result of 
either haematogenous spread, possibly from pulmonary sites or direct spread from 
accidental introduction of spores at contiguous sites1. With one exception (from India), all 
cases have either been in patients residing in, or originating from the Middle East, 
however  the organism has yet to be recovered from the environment. To date, including 
this case there have been 33 reported cases of cerebral R. mackenziei infection in the 
literature2,3. Where the outcome was known, mortality was reported in over 95%2. The 
majority of infections have occurred in immunocompetent individuals4  however, 
infections in patients with diabetes, haematological malignancies, and renal 
transplantation have also been documented. In a review of cerebral phaeohyphomycosis 
cases 2 of 13 Rhinocladiella cases were in renal transplant recipients5, and one in a 
haemodialysis patient. Rhinocladiella  infections are neurotropic, and to date, the brain is 
the only site of infection that has been reported.
Here we report, to the best of our knowledge, the first successfully treated case of 
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A 67 year old HIV-negative male of Iraqi origin with end stage renal failure secondary to 
urolithiasis underwent deceased donation renal transplant in August 2014. Induction 
immunosuppression consisted of alemtuzumab 30mg s/c and, methylprednisolone 
500mg IV. Prior to transplant a chest X-ray was normal. After transplantation he was 
maintained on tacrolimus monotherapy6 target range 9-14ng/ml trough level for the first 3 
months post transplant, followed by target range 5-9ng/ml thereafter. 
On 27 September 2014 he presented with a fever and non-specific right flank pain. 
Examination findings were non-diagnostic. His white blood cell (WBC) count was 5.99 × 
109/L (reference range 4.0-11 × 109/L) with a normal neutrophil count (5.54 × 109/L, 
reference range 2.0-7.5 × 109/L) and  lymphopenia (0.1 × 109/L, reference range 1.0-4.5), 
which had been persistent since his immunosuppression induction, and is an expected 
effect of alemtuzumab, with lymphocyte reconstitution to normal levels occurring between 
7 and 9 months post renal transplant. C-reactive protein was elevated, however, at 33 
mg/L (reference  <10 mg/L). Trans-thoracic echocardiogram (TTE) revealed mild-
moderate aortic stenosis and a tricuspid mass, which had been present in 2011 and may 
have represented a persistent vegetation (haemodialysis had been complicated by an 
episode of Staphylococcus aureus infective endocarditis in October 2011). On this 
occasion Enterococcus faecalis was isolated from three pairs of blood cultures.  A 
putative diagnosis of infective endocarditis was made and he was started on intravenous 
amoxicillin 2 g four-hourly. A trans-oesophageal echocardiogram (TOE) carried out on 7 
October 2014 did not confirm the presence of any vegetations.  However, on 10 October 
2014 an abdominal ultrasound demonstrated the presence of two echo poor areas in the 
spleen (2.0 cm and 2.6 cm), which were considered likely to represent splenic 
abscesses. The amoxicillin was continued for 6 weeks.
On 18th October 2014 the patient developed a right sided facial weakness and 
expressive dysphasia. Though able to mobilise independently, his gait was now unsteady 
and he had developed a right pronator drift. There was no headache or fever and the 
patient remained haemodynamically stable. A contrast-enhanced computed tomography 
(CT) scan on 21 of October 2014 (day 0) demonstrated a 2.5 cm ring-enhancing lesion 
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left posterior frontal lobe, which was considered most likely to represent an abscess 
(Figure 1a). 
On day 1 the patient was referred to neurosurgery and image-guided aspiration of 
the abscess was undertaken. Gram-film of the black pus aspirated showed no bacteria 
but profuse septate fungal hyphae, and fungal hyphae were also seen in a potassium 
hydroxide-calcofluor preparation.  In view of the detection of septate fungal hyphae the 
patient was commenced on iv voriconazole 6 mg/kg bd for the initial two doses, then 
4mg/kg 12 hourly. His tacrolimus was discontinued and he was commenced on 
prednisolone 20 mg/day as sole continuing immunosuppression. 
A darkly pigmented filamentous fungus grew on Sabouraud dextrose agar (30°C and 
35°C) after 3 days of incubation which produced terminal condia on poorly defined 
phialides. The patient’s serum was tested for galactomannan and beta-D-glucan 
(Fungitell). Galactomannan was negative with an index value of 0.068. The beta-D-
glucan level was 1727pg/mL (normal range <60pg/mL).
Resident in the UK since 1976, the patient had visited Iraq in 2003 as well as Jordan in 
2008 and Dubai in 2014. In view of his exposure to the Middle East, the presence of a 
solitary intracerebral abscess and the growth of a slow-growing, pigmented fungus a 
presumptive diagnosis of Rhinocladiella mackenziei cerebral phaeohyphomycosis was 
made. On day 6 the organism was identified as R. mackenziei following fungal DNA 
amplification and sequencing part of the large ribosomal subunit using primers NL1 
primers (5’ GCATATCAATAAGCGGAGGAAAG-3’) AND NL4 (5’-
GGTCCGTGTTTCAAGACGG-3’)7. Voriconazole was discontinued due to concerns 
about its effect on liver function, when the Alkaline phosphatase level rose to 965 iu/L 
(reference range 70-300) after 7 days of voriconazole; levels were not done. The patient 
was commenced on posaconazole gastro-resistant tablets (300 mg bd for 2 doses then 
300 mg daily) and liposomal amphotericin B 5 mg/kg/day. Susceptibility testing was 
performed by the PHE Mycology Reference Laboratory (MRL) in Bristol by Etest and 
results were available on day 8. The minimum inhibitory concentrations observed at 192 
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(resistant), itraconazole <0.03 mg/L (susceptible), voriconazole 0.06 mg/L (susceptible), 
posaconazole <0.03 mg/L (susceptible) and flucytosine 0.125 mg/L (susceptible). 
During the patient’s admission it was noted that he had been suffering with pain in his 
right ankle for five weeks. An MRI scan, showed appearances that were suspicious of 
septic arthritis, with surrounding myositis.  On day 1 a small amount of pus was aspirated 
from the joint. The sample was negative by bacterial culture and 16S PCR. However, on 
11 November 2014 a slow growing darkly pigmented mould was isolated and, confirmed 
to be R. mackenziei.  On day 2 an attempt was made to aspirate the presumed splenic 
abscesses. The fluid was negative for both bacteria and fungi by Gram-film, culture, 16 
and 18S PCR.  A contrast-enhanced CT head scan performed 5 days after the initial 
scan showed the continuing presence of a ring-enhanced frontal lesion, which had 
slightly reduced in size, although the area of surrounding oedema had enlarged. On day 
8 the serum posaconazole concentration was 2.15 mg/L (for clinical efficacy the target is 
1.25 mg/L). On day 9 the patient was converted from oral to IV posaconazole 300 
mg/day and liposomal amphotericin B was stopped. 
Repeat CT head scan on day 13 revealed a 2.5 cm lesion with a marginal decrease in 
surrounding oedema. The patient was returned to theatre for a repeat image guided 
aspiration of the lesion. The aspirated pus was negative on Gram stain but on day 23 R. 
mackenziei was isolated.  On day 17  iv posaconazole was discontinued (after a total of 8 
doses) and the patient re-started oral posaconazole gastro-resistant tablets 300 mg/day. 
The posaconazole level on the evening of day 17 was 2.26 mg/L (reference range >1.25 
mg/L). The patient was discharged home on day 25.
Despite almost two months of posaconazole, with good levels, there was a limited effect 
on the fungus as repeat outpatient CT head imaging on day 41 revealed an enlarged ring 
enhancing mass lesion maximal diameter of 2.9 cm. With the abscess close to the 
internal capsule, excision carried a significant risk of hemiparesis and speech 
disturbance. The patient had previously declined excision, but now was prepared to 
undergo the procedure. Intra-operatively a necrotic cavity was found however, in contrast 
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this area of the brain maximal debulking was carried out but complete excision was not 
possible.   IV flucytosine was added prior to surgery. The patient had  no post operative 
motor or sensory loss and on day 57, he was converted from iv to oral flucytosine 1.5 g 6-
hourly and oral posaconazole was continued. Pre-dose flucytosine levels were 
maintained between 25-50 mg/L. Once stabilised, flucyosine and posaconazole levels 
were monitored monthly. 
By day 59, the patient was considered suitable for hospital discharge.  Blood cultures 
obtained during the admission were negative after 4 weeks incubation. Whilst mobility 
and speech continued to improve, the patient reported right ankle pain, especially worse 
on palpation. An MRI scan of the ankle revealed osteomyelitis and abscess in the distal 
anterior fibula measuring approximately 2.3 x 2.5 x 2.6 cm (Fig. 2). There was also 
marked abnormality in the talus and extensive ankle soft tissue oedema. On day 111 he 
underwent excisional biopsy and insertion of cement spacer (containing voriconazole) to 
the right distal fibula. Fungal hyphae were seen in four fibula pus samples (microscopic 
appearance). R. mackenziei & E. faecalis were isolated on culture. Following the biopsy 
and insertion of cement spacer he was able to mobilise and put weight on his foot with 
the use of a stick. Oral posaconazole and flucytosine were continued and oral amoxicillin 
1g 8-hourly was added and continued for 4.5 months.  By day 173 the ring enhancing 
lesion in the posterior left frontal lobe had decreased slightly in size as compared to CT 
from day 111 (Fig. 1b).
At the time of writing, at almost five years since diagnosis, the patient had continued to 
improve in terms of mobility and speech.  Head CT imaging showed the lesion was 
stable, not increasing in size but with increased calcification. Beta-D-glucan testing 
showed initially very high levels of this fungal antigen, which have declined steadily 
during the treatment period (Fig. 3) and in July 2019 (day 1372)  was 38pg/ml (reference 
range <60mgl/L). In February 2019 (day 1190) the patients antifungal therapy  
(flucytosine and posaconazole) was stopped due to the response and possibility that the 
posaconazole was causing some leg pain. At the most recent follow up for his renal 
transplant (November 2019, 9 months after stopping antifungal therapy) the patient 
remained relatively well,  continues on prednisolone 7.5mg PO od as his only 
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variable Modification of Diet in Renal Disease Study). He was normotensive with no 
proteinuria.
Discussion
We report here the first case of disseminated R.mackenziei infection and one of the few 
cases of prolonged survival.  The ankle and brain lesions became apparent from 
symptomology at approximately the same time. Thus whilst this is speculation we 
consider that the organism was acquired by inhalation and then spread haematogenously 
to two sites, the brain and ankle concomitantly. This is consistent with the current view of 
how this kind of infection is acquired1
Cerebral phaeohyphomycosis usually presents with one or more of the following: limb 
weakness, hemiparesis, hemisenory loss, seizure and behavioural change. Fever and 
headache are uncommon presenting features. Radiographically, cerebral infection 
typically appears as a single ring-enhancing lesion. The presence of multiple lesions is 
most commonly associated with an immunocompromised status1.  Isolation of the fungus 
from biopsy samples or aspirated pus from brain lesions is required for definitive 
diagnosis.  
With the exception of a few isolated cases, combined antifungal chemotherapy and 
surgical debridement appear to be essential for successful outcome.  
Revanker et al. reviewed 101 cases of culture-proven cerebral phaeohyphomycosis 
reported in the literature from 1966 to 2002; and determined that excision of brain lesions 
may provide better results than simple aspiration or partial excision5. In this case due to 
the eloquence of the brain where the abscess was located aspiration was used on two 
occasions before an excision was attempted.  Most mature bacterial abscesses develop 
a thick capsule after 10 - 14 days and therefore become easier to excise over time, 
however we found in this fungal case that attempted excision was not possible as no 
capsule was present.  Maximal safe debulking was therefore used and is likely to have 
contributed to the successful management of this patient. Al-Abdely et al. (2005)8 report 
evidence of relapse of excised R. mackenziei  on itraconazole, following temporary 
improvement with voriconazole. The patient subsequently responded to posaconazole 
therapy albeit with significant neurological compromise. Furthermore, the superiority of 
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mackenziei infection has been demonstrated in a murine model9. There has been a case 
of documented treatment failure with posaconazole, however on that occasion the 
cerebral lesion was aspirated rather than excised and posaconazole monotherapy was 
used rather than combination therapy10.  Posaconazole is not known to penetrate into the 
CSF or cerebral tissue well. A case of Rhinocladiella cerebral abscess recently reported 
in a patient with Crohn’s disease and successfully treated with posaconazole showed that 
levels of posaconazole in the CSF were low (<10% of plasma levels), and  levels in brain 
tissues removed during varied though some showed slightly higher levels of 
posaconazole all were less than the plasma level3. The MICs were not reported in that 
study, but if cerebral tissue posaconazole levels our case were similar to those found by 
Barde et al (2019)3 ie 0.12 to 0.55 mg/L this would still be in excess of the posaconazole 
MIC (<0.03mg/L). Similar to our case, success was attributed to a combination of 
antifungals and surgical removal of the abscess. Use of beta-D-glucan to monitor the 
progress of treatment in this patient is novel for this fungus, but this approach has been 
reported in some other dematiacous fungal infections11, and this case shows its value in 
long term monitoring in a group of diseases where lack of diagnostics has been 
highlighted12.
A review of cerebral phaeohyphomycosis by Li & Sybren de Hoog1 identified that 
combination antifungal therapy was more frequently successful than monotherapy, a view 
reiterated in a more recent review12. This is a condition with very high mortality rates, and 
as such we opted for combination therapy of posaconazole plus flucytosine in addition to 
surgical excision. We advise therapeutic drug monitoring to ensure appropriate levels are 
reached and where there is relapse after initial response, antifungal susceptibility testing 
should be done and repeated to check for resistance that could have developed on 
therapy.
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Figure legends
Figure 1: Contrast enhanced CT head at a) day 0 and b) 6 months.
Figure 2   MRI of the right ankle
Figure 3 Time course of serum Beta D glucan, white stars are brain isolations of R 
mackenziei, black star is ankle isolation. 
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